Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332805 | 0.75 | NPC1 (0.31) | — | |
| SCHEMBL909643 | 0.70 | POLB (0.37) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL10208108 | 0.70 | POLB (0.37) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL20301699 | 0.70 | CSNK2A1 (0.38) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL8220963 | 0.70 | CSNK2A2 (0.38) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL11123892 | 0.70 | CYP2C19 (0.36) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL1832588 | 0.67 | LMNA (0.35) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL11640353 | 0.67 | LMNA (0.39) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL10210727 | 0.65 | LMNA (0.34) | LMNAPOLBRAB9ACYP2C19MAPT | |
| SCHEMBL11193212 | 0.65 | LMNA (0.34) | LMNAPOLBRAB9ACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2010-05-27 | — | — | US | disclosed |
| US-7674807-B2 | Heterocycle-substituted n-phenyl-phthalamide derivatives, related compounds and their use as insecticides | BAYER CROPSCIENCE AG (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-1727804-B1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2009-11-04 | — | — | EP | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| CN-1930129-A | N1- ((pyrazol-1-ylmethyl) -2-methylphenyl) -phthalamide derivative and related compound insecticide | BAYER CROPSCIENCE AG (DE) | 2007-03-14 | — | — | CN | disclosed |
| EP-1727804-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005095351-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2005-10-13 | — | — | WO | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | DDT, SQOR, CYP2S1 | LMNA 1336/4885POLB 4359/4885RAB9A 1199/4885 |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | CHRM1, KCNH1, DDT | LMNA 1631/4885POLB 4401/4885RAB9A 1055/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | LMNA 3074/4885POLB 3728/4885RAB9A 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.